Dupixent® (dupilumab) to treat chronic spontaneous urticaria (csu) advances in eu with positive chmp opinion

Recommendation for adults and adolescents based on phase 3 trials showing dupixent significantly reduced itch and hives at 24 weeks compared to placebo
REGN Ratings Summary
REGN Quant Ranking